EGF and non-small cell lung carcinoma: However, CIMAvax-EGF has been safely administered to stage IV NSCLC patients with progressive disease, in combination with nivolumab in a phase I/II trial, at the Roswell Park Comprehensive Cancer Center (Buffalo, NY).